Join for free and get access to the buyside
Get insights from the world's most influential hedge fund investors direct to your inbox
- © 2025 Buyside Digest
- Privacy Policy
- Disclaimer
- Sitemap
- Terms of Service
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Keywords/Themes | Theme Commentary | Pitches | Letter |
|---|---|---|---|---|---|---|---|---|---|
| 2025 Q4 | Feb 18, 2026 | Harvest Lane Asset Management | 3.3% | 9.1% | ASK.AX, AUB.AX, BBT.AX, DSE.AX, MYX.AX, NWC.AX, PBH.AX, PEK.AX, SLH.AX, STO.AX, WA8.AX, XAM.AX, XF1.AX | Absolute return, activism, Australia, Merger Arbitrage, special situations, takeovers | The fund participated in merger arbitrage opportunities across multiple sectors, with notable activity in pharmaceutical deals including Mayne Pharma Group Limited where the bidder attempted to walk from the deal. The fund was publicly outspoken about Cosette Pharmaceuticals acting in bad faith when trying to exit their acquisition of Mayne Pharma. May saw three deals in the copper space within a week, with the fund thinking at least one was ripe for a contest. New World Resources Limited saw significant action with multiple bidders, starting as a friendly scheme and ultimately seeing nine bids total with Kinterra Capital emerging as the victor. | MYX AU XF1 AU STO AU |
View |
| 2025 Q4 | Jan 7, 2026 | HalvioCapital | 5.6% | 0.0% | BKM.SI, CPH.TO, EDU.AX, FILA.MI, LNF.TO, MCCK, MYX.AX, NLOP | international, Japan, Merger Arbitrage, real estate, small caps, value | Manager focuses on undervalued securities across multiple markets, highlighting companies trading below intrinsic value such as TOC Co. with real estate worth ¥184B against ¥75B market cap, and FILA trading at attractive enterprise value multiples. The approach emphasizes finding bargains in less picked-over international markets. Japan basket represents a significant holding with focus on corporate governance reforms under new Prime Minister Sanae Takaichi. Manager sees opportunity in companies with excess cash being forced to improve capital allocation, with ¥83 trillion in corporate cash providing catalyst for shareholder returns. Portfolio concentrated in smaller companies across multiple geographies including Australian micro-caps, Canadian small caps, and niche industrial businesses. Manager seeks opportunities in less efficient markets where smaller companies may be mispriced or overlooked by institutional investors. | View |
| Date | Pitch Type | Author | Company | Industry | Sub Industry | Bull / Bear | Stock Exchange | Keywords | Action |
|---|---|---|---|---|---|---|---|---|---|
| Jan 22, 2026 | Twitter / X | @fabreres | Mayne Pharma Group Limited | Health Care | Pharmaceuticals | Bull | Australian Stock Exchange | Australia, Cosette, FIRB, Mayne, Myx, Photonics, Rail, Trial | View Pitch |
| Oct 15, 2025 | Substack | Triples Investing | Mayne Pharma | Health Care | Drug Manufacturers - General | Bull | acquisition, Australian courts, Cosette, FIRB, legal battle, Material Adverse Change, Mayne Pharma, oral contraceptive, pharmaceuticals, Revenue Growth | View Pitch |
| Manager Name | Fund Name | Fund AUM | Invested Value | Portfolio Weight | Shares Owned | Shares Bought / Sold During Quarter | % Bought / Sold During Quarter | % of Shares Outstanding Owned |
|---|---|---|---|---|---|---|---|---|
| No investor data available. | ||||||||